Pre- and early postnatal farm exposure was found to be associated with reduced incidence of atopic dermatitis in infants.
Therapy-induced ocular adverse events may be associated with pre-existing dry eye disease, eyelid eczema, and a history of a food allergy, among other conditions.
Dupilumab displayed significant reductions in work and school absenteeism with associated cost savings.
Skin colonization by Staphylococcus aureus is associated with the risk for developing AD, and infants who do not develop AD primarily exhibit acquisition of dysfunctional mutations in the S. aureus quorum-sensing system.
Children with asthma and atopic dermatitis who live in urban areas may be at a higher risk for poor sleep outcomes.
For patients with atopic dermatitis and moderate-to-severe pruritus, nemolizumab results in a greater reduction in pruritus than placebo.
Skin dryness, dust exposure, and distress play an essential role in the exacerbation of atopic dermatitis in the adult population.
Positive results from the second phase 3 study of upadacitinib (Rinvoq; AbbVie) showed that it met all primary and secondary end points for the treatment of moderate to severe atopic dermatitis.
The FDA has accepted for review the Biologics License Application (BLA) for tralokinumab.
Dupilumab provides long-term control of AD and prevents disease flares, which may help reduce the need for escalation and/or intensification of therapy.